Pasithea Therapeutics Corp.
KTTANASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $13.00M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $0.28$2.06
- Volume (live)
- -
- Avg. volume (3M)
- 210.74K
Pasithea Therapeutics (KTTA) Stock Price & Financial Analysis
Pasithea Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $0.34 - $0.47 |
|---|---|
| 52-Week High | $2.06 |
| 52-Week Low | $0.28 |
| Open | $0.45 |
| Volume (last close) | 1.53M |
| Average Volume (3M) | 210.74K |
| 50-Day MA | $0.50 |
|---|---|
| 200-Day MA | $0.65 |
| 1-Year Change | −39.01% |
| Market Cap | 13.00M |
|---|---|
| Shares Outstanding | 32.10M |
| Price to Book (P/B) | 0.26 |
| EV/EBITDA | 1.35 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Pasithea Therapeutics at a Glance
As of the Oct 23, 2026 close, Pasithea Therapeutics (KTTA) has a market capitalization of $13.00M.
As of its latest reported balance sheet, it holds $45.66M in cash and securities against $0.00 of debt, a net cash position of $45.66M.
Pasithea Therapeutics does not currently pay a dividend.
The share price is down 39.0% over the past year. At $0.40 (the Oct 23, 2026 close) it sits near the bottom of its 52-week range of $0.28 to $2.06, below its 200-day moving average of $0.65.
Frequently Asked Questions About Pasithea Therapeutics
What is the current stock price for KTTA?
As of the Oct 23, 2026 close, KTTA stock trades at $0.40. The 52-week range is $0.28–$2.06, with a day range of $0.34–$0.47.
What is the P/E ratio for KTTA?
The P/E ratio (Price-to-Earnings) for KTTA is shown in the Key Statistics section. This valuation metric helps compare Pasithea Therapeutics Corp. to industry peers.
Does KTTA pay dividends?
Pasithea Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for KTTA?
Analyst ratings and recommendations for KTTA are displayed in the Analyst Consensus section, including buy/hold/sell distribution and 12-month price targets.
What is the market cap of KTTA?
As of the Oct 23, 2026 close, Pasithea Therapeutics's market capitalization is $13.0M, classifying it as a micro-cap company. Pasithea Therapeutics operates in the Healthcare sector within the Biotechnology industry.